Gonzalez Francisco-Jesus, Quesada Ana-Rodriguez, Sevilla Isabel, Baca Juan-Javier, Medina Miguel-Angel, Amores Jose, Diaz Juan Miguel, Rius-Diaz Francisca, Marques Eduardo, Alba Emilio
Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Malaga, Spain.
J Cell Mol Med. 2007 Jan-Feb;11(1):120-8. doi: 10.1111/j.1582-4934.2007.00005.x.
Angiogenesis, resulting from an imbalance between angiogenic activator factors and inhibitors, is required for tumour growth and metastasis. The determination of the circulating concentration of all angiogenic factors (activators and inhibitors) is not feasible at present. We have evaluated diagnostic and prognostic values of the measurement of serum angiogenic activity in colorectal carcinoma (CRC) patients. Serum proliferative activity (PA) on human umbilical vein endothelial cells (HUVEC) in vitro, and serum vascular endothelial growth factor (VEGF) levels were determined by ELISA in 53 patients with primary CRC, 16 subjects with non-neoplastic gastrointestinal disease (SC) and 34 healthy individuals. Data were compared with clinical outcome of the patients. Although serum from CRC patients significantly increased the PA of HUVEC, compared to culture control (HUVEC in medium + 10% foetal bovine serum (FBS); P < 0.001); our results indicate that serum PA in CRC patients was similar to that of SC or healthy individuals. There was no correlation between serum PA and circulating VEGF concentrations. Surgery produced a decrease of PA at 8 hrs after tumour resection in CRC patients compared to pre-surgery values (186 +/- 47 versus 213 +/- 41, P < 0.001). However, an increase in serum VEGF values was observed after surgery (280 [176-450] versus 251 [160-357] pg/ml, P = 0.004). Patients with lower PA values after surgery showed a worse outcome that those with higher PA values. Therefore, this study does not support a diagnostic value for serum angiogenic activity measured by proliferative activity on HUVEC but suggests it could have a prognostic value in CRC patients.
血管生成是肿瘤生长和转移所必需的,它由血管生成激活因子和抑制剂之间的失衡引起。目前测定所有血管生成因子(激活因子和抑制剂)的循环浓度是不可行的。我们评估了测量结直肠癌(CRC)患者血清血管生成活性的诊断和预后价值。通过酶联免疫吸附测定法(ELISA)测定了53例原发性CRC患者、16例非肿瘤性胃肠道疾病(SC)患者和34名健康个体的人脐静脉内皮细胞(HUVEC)体外血清增殖活性(PA)以及血清血管内皮生长因子(VEGF)水平。将数据与患者的临床结果进行了比较。尽管与培养对照(培养基中的HUVEC + 10%胎牛血清(FBS))相比,CRC患者的血清显著增加了HUVEC的PA(P < 0.001);但我们的结果表明,CRC患者的血清PA与SC患者或健康个体的血清PA相似。血清PA与循环VEGF浓度之间没有相关性。与手术前的值相比,CRC患者肿瘤切除后8小时PA下降(186 +/- 47对213 +/- 41,P < 0.001)。然而,手术后观察到血清VEGF值增加(280 [176 - 450]对251 [160 - 357] pg/ml,P = 0.004)。手术后PA值较低的患者比PA值较高的患者预后更差。因此,本研究不支持通过HUVEC增殖活性测量血清血管生成活性的诊断价值,但表明其在CRC患者中可能具有预后价值。